Anti-il-6 antibodies, compositions, methods and uses

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/13 (2006.01) A01H 5/00 (2006.01) A01K 67/00 (2006.01) A61K 39/395 (2006.01) A61M 37/00 (2006.01) C07H 21/04 (2006.01) C07K 16/00 (2006.01) C07K 16/24 (2006.01) C07K 16/46 (2006.01) C12N 15/00 (2006.01) C12P 21/02 (2006.01)

Patent

CA 2467719

The present invention relates to at least one novel chimeric, humanized or CDR- grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, methods of making and using thereof, including therapeutic compositions, methods and devices.

L'invention concerne au moins un nouvel anticorps anti-IL-6 chimère, humanisé ou auquel a été greffée une région déterminant la complémentarité (CDR) dérivée de l'anticorps murin CLB-8, ainsi que des acides nucléiques isolés qui codent au moins ledit anticorps anti-IL-6, des vecteurs, des cellules hôtes, des animaux ou des plantes transgéniques, des méthodes de production et d'utilisation de celui-ci, et des compositions thérapeutiques, des méthodes et des dispositifs associés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Anti-il-6 antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-il-6 antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-il-6 antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1850292

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.